SMN1 and proximal spinal muscular atrophy: There are currently three therapeutic options available for SMA patients that have been developed based on the understanding of the molecular basis of SMA (Nusinersen, Onasemnogene abeparvovec and Risdiplam) and which focus on SMN1 gene modification or replacement or RNA modulation [16].